First results of the randomized, phase 3 CheckMate 648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone. Standard...
Read MoreA 2-year update of the CheckMate 9LA trial shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung...
Read MoreAddition of 177Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomized, phase 3 VISION trial....
Read MoreRBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumor immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial. Targeting cytosolic nucleic...
Read MoreFirst results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling of solid tumors in young patients. Next generation sequencing (NGS) assays are now a standard part of clinical care for many adult solid...
Read More
Are you caught up on trials on multiple sclerosis that have been released from AAN 2021? Test your...
Read MoreElectronic monitoring of Covid-19 symptoms wins high marks from patients In the 1980s the emergence of a previously unknown, lethal disease—acquired immune deficiency syndrome or AIDS, as it rapidly became known—rocked the world...
Read MoreGood anti-tumor activity and manageable safety profile seen When added to concurrent chemoradiation therapy (cCRT), pembrolizumab—a highly selective humanized monoclonal anti-PD-1 antibody—showed promising antitumor activity in...
Read MoreConfirmed response seen in patients who relapse after osimertinib Patients with non-small cell lung cancer (NSCLC) who had relapsed after an initial response to osimertinib therapy may benefit from treatment with the combination...
Read MoreObjective response observed at 1.4 months Targeted therapies have greatly improved outcomes in non-small cell lung cancer (NSCLC), but for patients who progress on those therapies, the prognosis is poor, which explains the...
Read MoreSurvival benefit seen in early-stage HER-2 negative breast cancer with BRCA1/2 mutations Adding 12 months of treatment with the PARP inhibitor olaparib following completion of standard therapies significantly increased invasive...
Read MoreSignificant improvements in mortality among non-small cell lung cancer (NSCLC) cancer patients have been reported over the past 2 decades, according to Surveillance, Epidemiology, and End Results Program (SEER) data. The timing...
Read MoreLiquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence in patients with early-stage non-small cell lung cancer (NSCLC). Due to low ctDNA levels in...
Read MoreHerpes zoster (HZ) is prevalent in patients with Chronic Lymphocytic Leukemia (CLL) and affects younger patients who require chemotherapy. The risk of developing HZ increases in recipients of first and second line chemotherapy....
Read MoreSurvival is significantly improved by calendar period among patients diagnosed after 2004 and treated in the era of advanced therapies. Females and younger patients had a higher probability of long term survival. The survival of...
Read MoreA 24-month phone and app/web-based diet and physical activity intervention that was successful for weight loss in the general population did not result in greater weight loss or improvement in cardiovascular (CV) risk factors...
Read MoreThis study demonstrated for the first time that human peripheral blood mononuclear cells (PBMCs) from chronic lymphocytic leukemia (CLL) patients can be converted into NK cells, CD8+ T cells, NKT cells, and TCRγδ T cells...
Read MorePalliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial. Integrated palliative and oncology care (IPC) as part of...
Read MoreProgression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with...
Read MoreEvidence indicates that balancing treatment efficacy with complication risk is critically important for older adults with non-Hodgkin’s lymphoma (NHL); however, the survival outcomes, rates of toxicities, and healthcare...
Read More
